| (Values in U.S. Thousands) | Sep, 2020 | Jun, 2020 | Mar, 2020 | Dec, 2019 | Sep, 2019 |
| Sales | 30 | 0 | 0 | 290 | 0 |
| Sales Growth | unch | unch | -100.00% | unch | unch |
| Net Income | -17,040 | -13,530 | -11,550 | -12,690 | -15,860 |
| Net Income Growth | -25.94% | -17.14% | +8.98% | +19.99% | -31.18% |
Cellular Biomedicine (CBMG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments utilizing proprietary cell technologies for the treatment of a range of cancers; joint disease and central nervous system diseases. Cellular Biomedicine Group Inc. is headquartered in Palo Alto, California.
Fiscal Year End Date: 12/31